1
|
Lin M, Pham CD, Ta RT, Manning HC. cGMP compliant one-step, one-pot automated [ 18F]FBnTP production for clinical imaging of mitochondrial activity. EJNMMI Radiopharm Chem 2024; 9:51. [PMID: 38935218 PMCID: PMC11211300 DOI: 10.1186/s41181-024-00274-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Accepted: 05/15/2024] [Indexed: 06/28/2024] Open
Abstract
BACKGROUND 4-[18F]fluorobenzyl-triphenylphosphonium ([18F]FBnTP) is a lipophilic cation PET tracer. The cellular uptake of [18F]FBnTP is correlated with oxidative phosphorylation by mitochondria, which has been associated with multiple critical diseases. To date, [18F]FBnTP has been successfully applied for imaging myocardial perfusion, assessment of severity of coronary artery stenosis, delineation of the ischemic area after transient coronary occlusion, and detection/quantification of apoptosis in various animal models. Recent preclinical and clinical studies have also expanded the possibilities of using [18F]FBnTP in oncological diagnosis and therapeutic monitoring. However, [18F]FBnTP is typically prepared through a tediously lengthy four-step, three-pot reaction and required multiple synthesizer modules; Thus, such an approach remains a challenge for this promising radiopharmaceutical to be implemented for routine clinical studies. Herein, we report an optimized one-step, one-pot automated approach to produce [18F]FBnTP through a single standard commercially-available radiosynthesizer that enables centralized production for clinical use. RESULTS The fully automated production of [18F]FBnTP took less than 55 min with radiochemical yields ranging from 28.33 ± 13.92% (non-decay corrected), apparent molar activity of 69.23 ± 45.62 GBq/µmol, and radiochemical purities of 99.79 ± 0.41%. The formulated [18F]FBnTP solution was determined to be sterile and colorless with a pH of 4.0-6.0. Our data has indicated no observable radiolysis after 8 h from the time of final product formulation and maximum assay of 7.88 GBq. CONCLUSIONS A simplified and cGMP-compliant radiosynthesis of [18F]FBnTP has been established on the commercially available synthesizer in high activity concentration and radiochemical purity. While the preclinical and clinical studies using [18F]FBnTP PET are currently underway, the automated approaches reported herein facilitate clinical adoption of this radiotracer and warrant centralized production of [18F]FBnTP for imaging multiple patients.
Collapse
Affiliation(s)
- Mai Lin
- Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA
| | - Cong-Dat Pham
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Robert T Ta
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - H Charles Manning
- Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
| |
Collapse
|
2
|
Lu Y, Collins J, Lin KS, van Dam RM. Scalable droplet-based radiosynthesis of [ 18F]fluorobenzyltriphenylphosphonium cation ([ 18F]FBnTP) via a "numbering up" approach. LAB ON A CHIP 2024; 24:728-737. [PMID: 38240629 PMCID: PMC10869106 DOI: 10.1039/d3lc01068f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/15/2024]
Abstract
The [18F]fluorobenzyltriphenylphosphonium cation ([18F]FBnTP) has emerged as a highly promising positron emission tomography (PET) tracer for myocardial perfusion imaging (MPI) due to its uniform distribution in the myocardium and favorable organ biodistribution demonstrated in preclinical studies. However, a complex and low-efficiency radiosynthesis procedure has significantly hindered its broader preclinical and clinical explorations. Recently, Zhang et al. developed a pinacolyl arylboronate precursor, enabling a one-step synthesis process that greatly streamlines the production of [18F]FBnTP. Building upon this progress, our group successfully adapted the approach to a microdroplet reaction format and demonstrated improved radiosynthesis performance in a preliminary optimization study. However, scaling up to clinical dose amounts was not explored. In this work, we demonstrate that scale-up can be performed in a straightforward manner using a "numbering up" strategy (i.e. performing multiple droplet reactions in parallel and pooling the crude products). The resulting radiochemical yield after purification and formulation was high, up to 66 ± 1% (n = 4) for a set of experiments involving pooling of 4 droplet reactions, accompanied by excellent radiochemical purity (>99%) and molar activity (339-710 GBq μmol-1). Notably, we efficiently achieved sufficient activity yield (0.76-1.84 GBq) for multiple clinical doses from 1.6 to 3.7 GBq of [18F]fluoride in just 37-47 min.
Collapse
Affiliation(s)
- Yingqing Lu
- Crump Institute for Molecular Imaging, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
- Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA
| | - Jeffrey Collins
- Crump Institute for Molecular Imaging, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
- Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, USA
| | - Kuo-Shyan Lin
- Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada
- Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - R Michael van Dam
- Crump Institute for Molecular Imaging, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
- Department of Molecular & Medical Pharmacology, UCLA, Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA
| |
Collapse
|
3
|
Holt DP, Dannals RF. An improved radiosynthesis of [ 18 F]FAraG, a PET radiotracer for imaging T-cell activation. J Labelled Comp Radiopharm 2022; 65:302-308. [PMID: 36000273 PMCID: PMC9826029 DOI: 10.1002/jlcr.3999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 08/15/2022] [Indexed: 01/11/2023]
Abstract
In this concise practitioner protocol, the radiochemical synthesis of 2'-deoxy-2'-[18 F]fluoro-9-β-d-arabinofuranosylguanine ([18 F]FAraG) suitable for human positron emission tomography (PET) studies is described and the results from validation productions are presented. The high specific activity (sometimes referred to as molar activity) radiotracer product is prepared as a sterile, apyrogenic solution that conforms to current Good Manufacturing Practice (cGMP) requirements established by the U.S. Food and Drug Administration.
Collapse
Affiliation(s)
- Daniel P. Holt
- Division of Nuclear Medicine, Department of RadiologyThe Johns Hopkins University School of MedicineBaltimoreMarylandUSA
| | - Robert F. Dannals
- Division of Nuclear Medicine, Department of RadiologyThe Johns Hopkins University School of MedicineBaltimoreMarylandUSA
| |
Collapse
|
4
|
An Automated Multidose Synthesis of the Potentiometric PET Probe 4-[ 18F]Fluorobenzyl-Triphenylphosphonium ([ 18F]FBnTP). Mol Imaging Biol 2019; 20:205-212. [PMID: 28905308 DOI: 10.1007/s11307-017-1119-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
PURPOSE The aim of this study was the automated synthesis of the mitochondrial membrane potential sensor 4-[18F]fluorobenzyl-triphenylphosphonium ([18F]FBnTP) on a commercially available synthesizer in activity yields (AY) that allow for imaging of multiple patients. PROCEDURES A three-pot, four-step synthesis was implemented on the ELIXYS FLEX/CHEM radiosynthesizer (Sofie Biosciences) and optimized for radiochemical yield (RCY), radiochemical purity (RCP) as well as chemical purity during several production runs (n = 24). The compound was purified by solid-phase extraction (SPE) with a Sep-Pak Plus Accell CM cartridge, thereby avoiding HPLC purification. RESULTS Under optimized conditions, AY of 1.4-2.2 GBq of [18F]FBnTP were obtained from 9.4 to 12.0 GBq [18F]fluoride in 90-92 min (RCY = 28.6 ± 5.1 % with n = 3). Molar activities ranged from 80 to 99 GBq/μmol at the end of synthesis. RCP of final formulations was > 99 % at the end of synthesis and > 95 % after 8 h. With starting activities of 23.2-33.0 GBq, RCY decreased to 16.1 ± 0.4 % (n = 3). The main cause of the decline in RCY when high amounts of [18F]fluoride are used is radiolytic decomposition of [18F]FBnTP during SPE purification. CONCLUSIONS In initial attempts, the probe was synthesized with RCY < 0.6 % when starting activities up to 44.6 GBq were used. Rapid radiolysis of the intermediate 4-[18F]fluorobenzaldehyde and the final product [18F]FBnTP during purification was identified as the main cause for low yields in high-activity runs. Radiolytic decomposition was hindered by the addition of radical scavengers during synthesis, purification, and formulation, thereby improving AY and RCP. The formulated probe in injectable form was synthesized without the use of HPLC and passed all applicable quality control tests.
Collapse
|
5
|
Azad BB, Holt DP, Ravert HT, Horti AG, Dannals RF. An optimized radiosynthesis of [ 18 F]FNDP, a positron emission tomography radiotracer for imaging soluble epoxide hydrolase (sEH). J Labelled Comp Radiopharm 2018; 61:567-572. [PMID: 29529708 PMCID: PMC6574083 DOI: 10.1002/jlcr.3620] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Revised: 02/27/2018] [Accepted: 03/01/2018] [Indexed: 01/16/2023]
Abstract
In this concise practitioner protocol, the radiochemical synthesis of [18 F]FNDP suitable for human positron emission tomography studies is described and the results from validation productions are presented. The high specific activity radiotracer product is prepared as a sterile, apyrogenic solution that conforms to current Good Manufacturing Practice requirements.
Collapse
Affiliation(s)
- Babak Behnam Azad
- Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Daniel P Holt
- Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Hayden T Ravert
- Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Andrew G Horti
- Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Robert F Dannals
- Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
6
|
Gobbi LC, Knust H, Körner M, Honer M, Czech C, Belli S, Muri D, Edelmann MR, Hartung T, Erbsmehl I, Grall-Ulsemer S, Koblet A, Rueher M, Steiner S, Ravert HT, Mathews WB, Holt DP, Kuwabara H, Valentine H, Dannals RF, Wong DF, Borroni E. Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer’s Disease with Positron Emission Tomography. J Med Chem 2017; 60:7350-7370. [DOI: 10.1021/acs.jmedchem.7b00632] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Luca C. Gobbi
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Henner Knust
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Matthias Körner
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Michael Honer
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Christian Czech
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Sara Belli
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Dieter Muri
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Martin R. Edelmann
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Thomas Hartung
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Isabella Erbsmehl
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Sandra Grall-Ulsemer
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Andreas Koblet
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Marianne Rueher
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Sandra Steiner
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | | | | | | | | | | | | | | | - Edilio Borroni
- Pharma
Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| |
Collapse
|
7
|
Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography. Molecules 2017; 22:molecules22040562. [PMID: 28358340 PMCID: PMC6154634 DOI: 10.3390/molecules22040562] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Revised: 02/14/2017] [Accepted: 02/20/2017] [Indexed: 12/12/2022] Open
Abstract
Coronary artery disease (CAD) is the leading cause of death in the world. Myocardial perfusion imaging (MPI) plays a significant role in non-invasive diagnosis and prognosis of CAD. However, neither single-photon emission computed tomography nor positron emission tomography clinical MPI agents can absolutely satisfy the demands of clinical practice. In the past decades, tremendous developments happened in the field of 18F-labeled MPI tracers. This review summarizes the current state of 18F-labeled MPI tracers, basic research data of those tracers, and the future direction of MPI tracer research.
Collapse
|
8
|
van der Born D, Pees A, Poot AJ, Orru RVA, Windhorst AD, Vugts DJ. Fluorine-18 labelled building blocks for PET tracer synthesis. Chem Soc Rev 2017; 46:4709-4773. [DOI: 10.1039/c6cs00492j] [Citation(s) in RCA: 113] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This review presents a comprehensive overview of the synthesis and application of fluorine-18 labelled building blocks since 2010.
Collapse
Affiliation(s)
- Dion van der Born
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Anna Pees
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Alex J. Poot
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Romano V. A. Orru
- Department of Chemistry and Pharmaceutical Sciences and Amsterdam Institute for Molecules
- Medicines & Systems (AIMMS)
- VU University Amsterdam
- Amsterdam
- The Netherlands
| | - Albert D. Windhorst
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Danielle J. Vugts
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| |
Collapse
|
9
|
Zhang Z, Zhang C, Lau J, Colpo N, Bénard F, Lin KS. One-step synthesis of 4-[(18) F]fluorobenzyltriphenylphosphonium cation for imaging with positron emission tomography. J Labelled Comp Radiopharm 2016; 59:467-71. [PMID: 27578168 DOI: 10.1002/jlcr.3436] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2016] [Revised: 07/26/2016] [Accepted: 07/29/2016] [Indexed: 02/01/2023]
Abstract
4-[(18) F]Fluorobenzyltriphenylphosphonium cation ((18) F-FBnTP) is a promising negative membrane potential targeting positron emission tomography tracer. However, the reported multistep radiolabeling approach for the synthesis of (18) F-FBnTP poses a challenge for routine clinical applications. In this study, we demonstrated that (18) F-FBnTP can be prepared in good conversion yields (~60%, nondecay corrected) in just one step via a copper-mediated (18) F-fluorination reaction using a pinacolyl arylboronate precursor. In addition, our data suggest that (18) F-labeled (phosphonium) cations can be efficiently prepared via a copper-mediated (18) F-fluoronation by using triflate as the counterion.
Collapse
Affiliation(s)
- Zhengxing Zhang
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Chengcheng Zhang
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Joseph Lau
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Nadine Colpo
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - François Bénard
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.,Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Kuo-Shyan Lin
- Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada. .,Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
| |
Collapse
|
10
|
Ravert HT, Holt DP, Chen Y, Mease RC, Fan H, Pomper MG, Dannals RF. An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL. J Labelled Comp Radiopharm 2016; 59:439-50. [PMID: 27470935 DOI: 10.1002/jlcr.3430] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Revised: 07/02/2016] [Accepted: 07/04/2016] [Indexed: 11/07/2022]
Abstract
The radiosynthesis of [(18) F]DCFPyL on 2 distinct automated platforms with full regulatory compliant quality control specifications is described. The radiotracer synthesis was performed on a custom-made radiofluorination module and the Sofie Biosciences ELIXYS. The radiofluorination module synthesis was accomplished in an average of 66 minutes from end of bombardment with an average specific activity at end of synthesis (EOS) of 4.4 TBq/μmol (120 Ci/μmol) and an average radiochemical yield of 30.9% at EOS. The ELIXYS synthesis was completed in an average of 87 minutes with an average specific activity of 2.2 TBq/μmol (59.3 Ci/μmol) and an average radiochemical yield of 19% at EOS. Both synthesis modules produced large millicurie quantities of [(18) F]DCFPyL while conforming to all standard US Pharmacopeia Chapter <823> acceptance testing criteria.
Collapse
Affiliation(s)
- Hayden T Ravert
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
| | - Daniel P Holt
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ying Chen
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Ronnie C Mease
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Hong Fan
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Martin G Pomper
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Robert F Dannals
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
11
|
Holt DP, Ravert HT, Dannals RF. Synthesis and quality control of [(18) F]T807 for tau PET imaging. J Labelled Comp Radiopharm 2016; 59:411-5. [PMID: 27427174 DOI: 10.1002/jlcr.3425] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 06/08/2016] [Accepted: 06/10/2016] [Indexed: 11/06/2022]
Abstract
The detailed synthesis and quality control of [(18) F]T807, radiotracer for tau protein aggregate imaging, are described. The radiotracer synthesis was accomplished in an average of 48 min with an average specific activity at end-of-synthesis of over 4.4 TBq/µmole (120 Ci/µmole) and an average radiochemical yield of 32%. Compliance with all standard US Pharmacopeia Chapter <823> acceptance tests was observed.
Collapse
Affiliation(s)
- Daniel P Holt
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Hayden T Ravert
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Robert F Dannals
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
12
|
Ravert HT, Holt DP, Gao Y, Horti AG, Dannals RF. Microwave-assisted radiosynthesis of [(18) F]ASEM, a radiolabeled α7-nicotinic acetylcholine receptor antagonist. J Labelled Comp Radiopharm 2015; 58:180-2. [PMID: 25720955 DOI: 10.1002/jlcr.3275] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Revised: 01/14/2015] [Accepted: 01/18/2015] [Indexed: 11/07/2022]
Abstract
An improvement of the original radiochemical synthesis of [(18) F]ASEM, an α7-nicotinic acetylcholinergic receptor radioligand, is reported. The new procedure utilizes microwave-assisted radiofluorination. In addition, a new preparative HPLC method was developed to eliminate a chemical impurity in the final product. Quality control procedures were also enhanced to improve detection of product with enhanced resolution of potential impurities. [(18) F]ASEM was produced in 20.1 ± 8.9% non-decay corrected (NDC) yield with an average synthesis time of 57 min and an average specific radioactivity of 856 ± 332 GBq/µmol (23 ± 9 Ci/µmol).
Collapse
Affiliation(s)
- Hayden T Ravert
- Division of Nuclear Medicine, Department of Radiology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Nelson B1-152, Baltimore, MD, 21287, USA
| | | | | | | | | |
Collapse
|